Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos

Un anticuerpo anti-Factor XI (FXI) purificado o un fragmento biologicamente activo del mismo que se unen especificamente al FXI humano descrito en la SEQ ID NO: 1, en donde dichos anticuerpo o fragmento biologicamente activo del mismo comprenden seis regiones determinantes de la complementariedad (CDR), en donde dichas regiones CDR tienen las secuencias de aminoacidos expuestas en las SEQ ID NO: 10, 11, 12, 13, 14 y 15. The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.